ATPS-05CHARACTERIZATION OF THE ACTIVITY OF AT13387, A NOVEL SECOND GENERATION HSP90 INHIBITOR AGAINST GLIOMAS
Alessandro Canella(Nationwide Children's Hospital), Vinay K. Puduvalli(The University of Texas MD Anderson Cancer Center), Dyvia Kesanakurti(Center for Neuro-Oncology), Prabakaran Nagarajan(The Ohio State University), Ji Young Yoo(The University of Texas MD Anderson Cancer Center), Balveen Kaur(Augusta University), Jihong Xu
Cited by 2
Related Papers
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses
|Proceedings of the National Academy of Sciences|2006|360
Glucose-Mediated N-glycosylation of SCAP Is Essential for SREBP-1 Activation and Tumor Growth
|Cancer Cell|2015|336
Inhibition of SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-1–Mediated Lipogenesis
|Clinical Cancer Research|2016|332
VEGF-specific Short Hairpin RNA–expressing Oncolytic Adenovirus Elicits Potent Inhibition of Angiogenesis and Tumor Growth
|Molecular Therapy|2007|150
RNA Nanoparticle-Based Targeted Therapy for Glioblastoma through Inhibition of Oncogenic miR-21
|Molecular Therapy|2017|147